載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$22.09
−US$0.02 · -0.09%
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
前收盤價
US$22.09
−US$0.02 · -0.09%
盤中時間採用ET。市場資料可能有所延遲。
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
日內區間
目前US$22.09
52週區間
目前US$22.09
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
98
深度低估
情緒
60
多空交錯
風險
44
風險偏高
動能
40
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
日內區間
目前US$22.09
52週區間
目前US$22.09
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.81億 USD | 6.31億 USD | 5.67億 USD | 4.64億 USD | 2.77億 USD |
| 銷貨成本 | 3.17億 USD | 2.54億 USD | 2.41億 USD | 2.54億 USD | 1.26億 USD |
| 毛利 | 4.63億 USD | 3.77億 USD | 3.26億 USD | 2.09億 USD | 1.51億 USD |
| 研究與開發 | — | — | — | 398.3萬 USD | 945.1萬 USD |
| 銷售、一般及管理費用 | 2.76億 USD | 1.83億 USD | 1.59億 USD | 1.72億 USD | 1.19億 USD |
| 營業費用 | 2.76億 USD | 2.07億 USD | 1.59億 USD | 1.76億 USD | 1.33億 USD |
| 利息收入 | 1128.9萬 USD | 1397.6萬 USD | 1561.5萬 USD | 104.7萬 USD | 1.2萬 USD |
| 利息支出 | 8231.2萬 USD | 7397.4萬 USD | 8333.9萬 USD | 6321.3萬 USD | 2101.4萬 USD |
| 折舊和攤銷 | 2.26億 USD | 1.69億 USD | 1.49億 USD | 1.39億 USD | 6891.7萬 USD |
| 營業利益 | 1.87億 USD | 1.7億 USD | 1.67億 USD | 3331.9萬 USD | 1762.8萬 USD |
| 淨利 | 6287萬 USD | 6919萬 USD | 4815.5萬 USD | −2500.2萬 USD | 7151.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2406.75萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1907.36萬0.02%787.4億 USD0.19%US$278.94+0.49%
Invesco Pharmaceuticals ETFPJP1418.7萬2.59%5.48億 USD0.58%US$122.88+1.56%
Avantis U.S. Small Cap Value ETFAVUV1050.55萬0.03%308.51億 USD0.25%US$119.64-0.41%
Invesco Biotechnology & Genome ETFPBE941.46萬2.23%4.22億 USD0.59%US$97.065+2.98%
Vanguard Extended Market ETFVXF925.14萬0.01%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH866.93萬1.88%4.62億 USD0.35%US$64.65+1.60%
Pacer US Small Cap Cash Cows ETFCALF680.89萬0.19%35.87億 USD0.59%US$54.66-0.16%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMInvesco Pharmaceuticals ETFPJPAvantis U.S. Small Cap Value ETFAVUVInvesco Biotechnology & Genome ETFPBEVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
